Literature DB >> 16904828

Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease.

L Blázquez1, D Otaegui, A Sáenz, C Paisán-Ruiz, J I Emparanza, J Ruiz-Martinez, F Moreno, J F Martí-Massó, A López de Munain.   

Abstract

Parkinson's disease (PD) is the second most common age-related neurodegenerative disease after Alzheimer's disease (AD). Common risk factors for both diseases have been explored to study potential etiologic interactions between these two neurodegenerative disorders. The APOE epsilon4 allele, previously associated with AD, has also been associated with risk of PD and with the presence of some clinical features in PD patients. However, the role of APOE epsilon4 allele in risk of PD remains unclear. We studied the distribution of APOE alleles in 276 unrelated familial and sporadic PD patients and in 212 controls. Patients and controls were classified by ethnicity. No genetic heterogeneity between Basques and people from other regions of Spain was found. No significant differences in APOE allele distribution between PD patients and controls were found; however, lower epsilon4 allele frequency was observed when the sporadic PD group was analyzed separately. By contrast, an increase in epsilon4 allele frequency was found in familial PD patients with cognitive decline. We conclude that the APOE epsilon4 allele may be associated with the risk of developing PD in isolated cases and that it is linked to the presence of cognitive decline in familial PD in our sample.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904828     DOI: 10.1016/j.neulet.2006.07.037

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T.

Authors:  S G Mueller; N Schuff; S Raptentsetsang; J Elman; M W Weiner
Journal:  Neuroimage       Date:  2008-04-22       Impact factor: 6.556

2.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

3.  APOE and LRPAP1 gene polymorphism and risk of Parkinson's disease.

Authors:  Neeraj Kumar Singh; Basu Dev Banerjee; Kiran Bala; Aldrin Anthony Dung Dung; Neelam Chhillar
Journal:  Neurol Sci       Date:  2014-02-07       Impact factor: 3.307

4.  Apolipoprotein E genotypes and the risk of Parkinson disease.

Authors:  Jianjun Gao; Xuemei Huang; Yikyung Park; Rui Liu; Albert Hollenbeck; Arthur Schatzkin; Richard B Mailman; Honglei Chen
Journal:  Neurobiol Aging       Date:  2011-07-08       Impact factor: 4.673

5.  Prion protein codon 129 polymorphism modifies age at onset of frontotemporal dementia with the C.709-1G>A progranulin mutation.

Authors:  Fermín Moreno; Ainhoa Alzualde; Pablo Martínez Camblor; Myriam Barandiaran; Vivianna M Van Deerlin; Alazne Gabilondo; José F Martí Massó; Adolfo López de Munain; Begoña Indakoetxea
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

Review 6.  Family history and APOE-4 genetic risk in Alzheimer's disease.

Authors:  Markus Donix; Gary W Small; Susan Y Bookheimer
Journal:  Neuropsychol Rev       Date:  2012-02-23       Impact factor: 7.444

7.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Authors:  Caroline H Williams-Gray; An Goris; Misuzu Saiki; Thomas Foltynie; D Alastair S Compston; Stephen J Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

8.  Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Authors:  Valérie Leduc; Dorothée Domenger; Louis De Beaumont; Daphnée Lalonde; Stéphanie Bélanger-Jasmin; Judes Poirier
Journal:  Int J Alzheimers Dis       Date:  2011-04-05

9.  An exploratory study on CLU, CR1 and PICALM and Parkinson disease.

Authors:  Jianjun Gao; Xuemei Huang; Yikyung Park; Albert Hollenbeck; Honglei Chen
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

Review 10.  Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.

Authors:  Fatemeh Nouri Emamzadeh
Journal:  J Mol Neurosci       Date:  2017-07-10       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.